| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Robotic Surgical Procedures | 19 | 2023 | 219 | 6.710 |
Why?
|
| Ureter | 16 | 2023 | 99 | 6.460 |
Why?
|
| Laparoscopy | 22 | 2023 | 521 | 6.110 |
Why?
|
| Ureteral Obstruction | 12 | 2023 | 105 | 4.890 |
Why?
|
| Robotics | 10 | 2023 | 108 | 4.270 |
Why?
|
| Vesico-Ureteral Reflux | 11 | 2023 | 87 | 3.460 |
Why?
|
| Urologic Surgical Procedures | 13 | 2022 | 61 | 2.960 |
Why?
|
| Kidney Pelvis | 7 | 2018 | 46 | 2.820 |
Why?
|
| Replantation | 8 | 2023 | 56 | 2.680 |
Why?
|
| Urology | 8 | 2023 | 87 | 2.470 |
Why?
|
| Pediatrics | 9 | 2024 | 1208 | 1.490 |
Why?
|
| Urinary Tract | 5 | 2019 | 67 | 1.400 |
Why?
|
| Hydronephrosis | 5 | 2019 | 38 | 1.280 |
Why?
|
| Urinary Bladder | 9 | 2024 | 257 | 1.250 |
Why?
|
| Kidney | 6 | 2020 | 1332 | 1.080 |
Why?
|
| Ureterostomy | 2 | 2017 | 6 | 1.070 |
Why?
|
| Urethral Obstruction | 8 | 2024 | 58 | 1.050 |
Why?
|
| Specialties, Surgical | 2 | 2019 | 85 | 1.030 |
Why?
|
| Hematuria | 2 | 2025 | 55 | 1.010 |
Why?
|
| Nephrectomy | 5 | 2022 | 180 | 0.970 |
Why?
|
| Child | 48 | 2025 | 25761 | 0.960 |
Why?
|
| Postoperative Complications | 14 | 2023 | 3144 | 0.900 |
Why?
|
| Lymphatic Vessels | 6 | 2024 | 36 | 0.870 |
Why?
|
| Stents | 4 | 2020 | 874 | 0.860 |
Why?
|
| Ambulatory Surgical Procedures | 2 | 2022 | 59 | 0.850 |
Why?
|
| Kidney Neoplasms | 4 | 2022 | 454 | 0.830 |
Why?
|
| Cystitis | 3 | 2016 | 51 | 0.820 |
Why?
|
| Urinary Bladder Neck Obstruction | 3 | 2018 | 30 | 0.820 |
Why?
|
| Humans | 107 | 2025 | 132083 | 0.810 |
Why?
|
| Spermatic Cord Torsion | 3 | 2019 | 16 | 0.790 |
Why?
|
| Infant | 32 | 2023 | 13040 | 0.780 |
Why?
|
| Fetal Diseases | 7 | 2024 | 462 | 0.770 |
Why?
|
| Priapism | 1 | 2022 | 12 | 0.760 |
Why?
|
| Near Miss, Healthcare | 1 | 2022 | 6 | 0.750 |
Why?
|
| Fellowships and Scholarships | 3 | 2018 | 323 | 0.740 |
Why?
|
| Ultrasonography, Prenatal | 8 | 2024 | 1010 | 0.720 |
Why?
|
| Child, Preschool | 29 | 2023 | 14719 | 0.700 |
Why?
|
| Financing, Organized | 1 | 2021 | 21 | 0.690 |
Why?
|
| Urinary Retention | 1 | 2021 | 19 | 0.690 |
Why?
|
| Equipment Design | 4 | 2018 | 611 | 0.680 |
Why?
|
| Treatment Outcome | 24 | 2023 | 13014 | 0.670 |
Why?
|
| Lymphangiogenesis | 6 | 2019 | 17 | 0.660 |
Why?
|
| Ecosystem | 1 | 2021 | 107 | 0.650 |
Why?
|
| Urinary Bladder Diseases | 3 | 2017 | 34 | 0.650 |
Why?
|
| Magnets | 1 | 2020 | 23 | 0.650 |
Why?
|
| Male | 55 | 2024 | 64904 | 0.610 |
Why?
|
| Kidney Transplantation | 3 | 2023 | 567 | 0.610 |
Why?
|
| Minimally Invasive Surgical Procedures | 6 | 2018 | 194 | 0.600 |
Why?
|
| Retrospective Studies | 34 | 2023 | 17367 | 0.590 |
Why?
|
| Fused Kidney | 1 | 2018 | 3 | 0.580 |
Why?
|
| Nephrolithiasis | 1 | 2018 | 15 | 0.580 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 344 | 0.570 |
Why?
|
| Urogenital Abnormalities | 2 | 2017 | 167 | 0.570 |
Why?
|
| Endothelial Cells | 11 | 2022 | 530 | 0.560 |
Why?
|
| Physicians, Women | 1 | 2018 | 52 | 0.550 |
Why?
|
| Dwarfism | 1 | 2018 | 104 | 0.540 |
Why?
|
| Anesthesia, General | 1 | 2018 | 124 | 0.540 |
Why?
|
| Urethra | 4 | 2015 | 90 | 0.540 |
Why?
|
| Stem Cells | 3 | 2013 | 732 | 0.530 |
Why?
|
| Engineering | 1 | 2017 | 7 | 0.530 |
Why?
|
| Severity of Illness Index | 2 | 2025 | 3083 | 0.530 |
Why?
|
| Genitalia | 1 | 2016 | 38 | 0.500 |
Why?
|
| Tissue Engineering | 2 | 2008 | 170 | 0.500 |
Why?
|
| Equipment and Supplies | 3 | 2025 | 28 | 0.500 |
Why?
|
| Adolescent | 26 | 2024 | 20532 | 0.500 |
Why?
|
| Female | 46 | 2024 | 70664 | 0.500 |
Why?
|
| Perineum | 1 | 2016 | 48 | 0.500 |
Why?
|
| Reoperation | 3 | 2020 | 854 | 0.490 |
Why?
|
| Twins, Conjoined | 1 | 2016 | 30 | 0.480 |
Why?
|
| Hypospadias | 4 | 2020 | 80 | 0.480 |
Why?
|
| Diseases in Twins | 1 | 2016 | 97 | 0.480 |
Why?
|
| Hospitals, Pediatric | 6 | 2025 | 780 | 0.480 |
Why?
|
| Operating Rooms | 1 | 2016 | 76 | 0.480 |
Why?
|
| Microcephaly | 1 | 2018 | 354 | 0.460 |
Why?
|
| Patient Transfer | 1 | 2016 | 110 | 0.460 |
Why?
|
| Endoscopy | 3 | 2017 | 281 | 0.460 |
Why?
|
| Kidney Calices | 1 | 2014 | 4 | 0.450 |
Why?
|
| Urinary Bladder, Neurogenic | 3 | 2023 | 46 | 0.450 |
Why?
|
| Urologic Diseases | 3 | 2019 | 45 | 0.450 |
Why?
|
| Urethral Diseases | 3 | 2020 | 20 | 0.440 |
Why?
|
| Down-Regulation | 5 | 2017 | 679 | 0.440 |
Why?
|
| Diverticulum | 1 | 2014 | 30 | 0.440 |
Why?
|
| Urogenital System | 2 | 2019 | 35 | 0.440 |
Why?
|
| Faculty, Medical | 2 | 2017 | 278 | 0.430 |
Why?
|
| Follow-Up Studies | 13 | 2019 | 5399 | 0.420 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2013 | 4 | 0.420 |
Why?
|
| Receptor, IGF Type 2 | 1 | 2013 | 8 | 0.410 |
Why?
|
| Fibroblast Growth Factor 10 | 1 | 2013 | 21 | 0.410 |
Why?
|
| Suture Techniques | 1 | 2015 | 190 | 0.410 |
Why?
|
| Calcitonin | 1 | 2013 | 32 | 0.410 |
Why?
|
| Infant, Newborn | 16 | 2020 | 8539 | 0.400 |
Why?
|
| Publications | 1 | 2013 | 35 | 0.400 |
Why?
|
| Urothelium | 1 | 2013 | 60 | 0.400 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2013 | 91 | 0.400 |
Why?
|
| Protein Precursors | 1 | 2013 | 156 | 0.380 |
Why?
|
| Lymphedema | 3 | 2022 | 21 | 0.380 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 288 | 0.370 |
Why?
|
| Fetus | 4 | 2023 | 598 | 0.370 |
Why?
|
| Ion Channels | 3 | 2024 | 206 | 0.370 |
Why?
|
| Pubic Symphysis | 1 | 2011 | 2 | 0.360 |
Why?
|
| Bone Plates | 1 | 2011 | 26 | 0.350 |
Why?
|
| Bladder Exstrophy | 1 | 2011 | 14 | 0.350 |
Why?
|
| Absorbable Implants | 1 | 2011 | 26 | 0.350 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2018 | 2168 | 0.350 |
Why?
|
| Clinical Trials as Topic | 3 | 2025 | 1158 | 0.350 |
Why?
|
| Bone Screws | 1 | 2011 | 53 | 0.340 |
Why?
|
| Leadership | 1 | 2013 | 246 | 0.340 |
Why?
|
| Pregnancy | 13 | 2024 | 7551 | 0.330 |
Why?
|
| Operative Time | 4 | 2020 | 190 | 0.320 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2010 | 12 | 0.320 |
Why?
|
| Testicular Neoplasms | 3 | 2021 | 131 | 0.320 |
Why?
|
| Glycosylation | 1 | 2010 | 126 | 0.320 |
Why?
|
| Meningomyelocele | 2 | 2017 | 254 | 0.310 |
Why?
|
| Kidney Diseases | 2 | 2011 | 488 | 0.310 |
Why?
|
| Cost of Illness | 1 | 2011 | 275 | 0.310 |
Why?
|
| Urachal Cyst | 1 | 2008 | 3 | 0.300 |
Why?
|
| Cystoscopy | 4 | 2016 | 46 | 0.300 |
Why?
|
| Cell Differentiation | 5 | 2013 | 1975 | 0.290 |
Why?
|
| Urologists | 2 | 2019 | 12 | 0.290 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 540 | 0.290 |
Why?
|
| Cryptorchidism | 5 | 2021 | 37 | 0.290 |
Why?
|
| Urinary Fistula | 2 | 2020 | 20 | 0.280 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1163 | 0.280 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2023 | 166 | 0.280 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2017 | 493 | 0.280 |
Why?
|
| United States | 13 | 2025 | 11630 | 0.270 |
Why?
|
| Homeodomain Proteins | 6 | 2017 | 573 | 0.270 |
Why?
|
| Urinary Tract Infections | 2 | 2023 | 317 | 0.270 |
Why?
|
| Nephrostomy, Percutaneous | 2 | 2017 | 21 | 0.270 |
Why?
|
| Mechanotransduction, Cellular | 4 | 2024 | 74 | 0.260 |
Why?
|
| DNA Methylation | 1 | 2013 | 1130 | 0.250 |
Why?
|
| Risk Assessment | 6 | 2019 | 3714 | 0.250 |
Why?
|
| Fetoscopy | 2 | 2022 | 449 | 0.240 |
Why?
|
| Self Report | 2 | 2019 | 553 | 0.240 |
Why?
|
| Specialization | 1 | 2005 | 80 | 0.220 |
Why?
|
| Animals | 17 | 2025 | 34951 | 0.220 |
Why?
|
| Cerebrospinal Fluid | 1 | 2024 | 98 | 0.210 |
Why?
|
| Cattle | 1 | 2025 | 571 | 0.210 |
Why?
|
| Receptor, Notch1 | 2 | 2017 | 77 | 0.210 |
Why?
|
| Gestational Age | 4 | 2020 | 1227 | 0.210 |
Why?
|
| Cicatrix | 2 | 2018 | 124 | 0.210 |
Why?
|
| Research | 1 | 2005 | 265 | 0.200 |
Why?
|
| Delphi Technique | 1 | 2024 | 240 | 0.200 |
Why?
|
| Renal Insufficiency | 2 | 2015 | 254 | 0.200 |
Why?
|
| Adult | 10 | 2022 | 31544 | 0.190 |
Why?
|
| Phenylephrine | 1 | 2022 | 40 | 0.190 |
Why?
|
| Signal Transduction | 3 | 2013 | 4725 | 0.190 |
Why?
|
| Ultrasonography, Doppler, Color | 2 | 2019 | 57 | 0.190 |
Why?
|
| Bacteriuria | 1 | 2023 | 81 | 0.190 |
Why?
|
| Prognosis | 7 | 2024 | 5006 | 0.180 |
Why?
|
| Hormones, Ectopic | 1 | 2001 | 7 | 0.180 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2022 | 62 | 0.180 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 235 | 0.180 |
Why?
|
| Myofibroma | 1 | 2021 | 9 | 0.180 |
Why?
|
| Consensus | 1 | 2024 | 656 | 0.180 |
Why?
|
| Home Care Services | 1 | 2022 | 73 | 0.180 |
Why?
|
| Nephrology | 1 | 2023 | 156 | 0.170 |
Why?
|
| Urodynamics | 2 | 2017 | 40 | 0.170 |
Why?
|
| Norepinephrine | 1 | 2001 | 166 | 0.170 |
Why?
|
| Penile Diseases | 1 | 2020 | 11 | 0.170 |
Why?
|
| Time Factors | 6 | 2017 | 6445 | 0.170 |
Why?
|
| Cutaneous Fistula | 1 | 2020 | 23 | 0.170 |
Why?
|
| ORAI1 Protein | 2 | 2017 | 6 | 0.170 |
Why?
|
| Amniotic Fluid | 3 | 2020 | 154 | 0.170 |
Why?
|
| Magnetic Phenomena | 1 | 2020 | 6 | 0.170 |
Why?
|
| Sex Distribution | 2 | 2018 | 324 | 0.160 |
Why?
|
| Swine | 2 | 2022 | 1197 | 0.160 |
Why?
|
| Herpesviridae Infections | 2 | 2012 | 146 | 0.160 |
Why?
|
| Mice | 11 | 2024 | 18565 | 0.160 |
Why?
|
| Cystography | 1 | 2019 | 2 | 0.160 |
Why?
|
| Nerve Block | 1 | 2020 | 63 | 0.160 |
Why?
|
| Anesthetics | 1 | 2020 | 78 | 0.160 |
Why?
|
| Regeneration | 2 | 2012 | 226 | 0.160 |
Why?
|
| Tretinoin | 3 | 2012 | 102 | 0.160 |
Why?
|
| Spermatic Cord | 1 | 2019 | 12 | 0.160 |
Why?
|
| Urinary Bladder Calculi | 1 | 1999 | 1 | 0.160 |
Why?
|
| Cyclophosphamide | 2 | 2013 | 425 | 0.160 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2017 | 120 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2001 | 246 | 0.150 |
Why?
|
| Circumcision, Male | 1 | 2019 | 25 | 0.150 |
Why?
|
| Urography | 2 | 2018 | 32 | 0.150 |
Why?
|
| Hypoglycemia | 1 | 2020 | 183 | 0.150 |
Why?
|
| Pilot Projects | 3 | 2020 | 1452 | 0.150 |
Why?
|
| Nephrolithotomy, Percutaneous | 1 | 2018 | 5 | 0.150 |
Why?
|
| Conflict of Interest | 1 | 2019 | 67 | 0.140 |
Why?
|
| Nervous System Malformations | 1 | 2020 | 132 | 0.140 |
Why?
|
| Prenatal Care | 2 | 2023 | 359 | 0.140 |
Why?
|
| Ultrasonography | 2 | 2020 | 989 | 0.140 |
Why?
|
| Child Health | 1 | 2019 | 68 | 0.140 |
Why?
|
| Pediatricians | 1 | 2019 | 72 | 0.140 |
Why?
|
| Device Removal | 1 | 2020 | 225 | 0.140 |
Why?
|
| Physical Examination | 1 | 2019 | 166 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2022 | 424 | 0.140 |
Why?
|
| Anesthesia | 1 | 2020 | 209 | 0.140 |
Why?
|
| Transplants | 1 | 2018 | 36 | 0.140 |
Why?
|
| Herpesvirus 8, Human | 3 | 2012 | 50 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 1292 | 0.140 |
Why?
|
| Acetylcholine Release Inhibitors | 1 | 2017 | 19 | 0.140 |
Why?
|
| Incidence | 7 | 2020 | 3365 | 0.140 |
Why?
|
| Computer-Assisted Instruction | 1 | 2017 | 54 | 0.130 |
Why?
|
| Endothelium, Lymphatic | 1 | 2017 | 9 | 0.130 |
Why?
|
| Nephrotomy | 1 | 2017 | 3 | 0.130 |
Why?
|
| Sampling Studies | 1 | 2017 | 77 | 0.130 |
Why?
|
| Career Choice | 1 | 2018 | 161 | 0.130 |
Why?
|
| Sacroiliac Joint | 1 | 2016 | 4 | 0.130 |
Why?
|
| Neurofibrosarcoma | 1 | 2016 | 5 | 0.130 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 241 | 0.130 |
Why?
|
| Epididymis | 1 | 2017 | 68 | 0.130 |
Why?
|
| Mentors | 1 | 2018 | 164 | 0.130 |
Why?
|
| Sacrum | 1 | 2016 | 31 | 0.130 |
Why?
|
| Spinal Nerve Roots | 1 | 2016 | 19 | 0.130 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2012 | 303 | 0.130 |
Why?
|
| Pelvic Bones | 1 | 2016 | 28 | 0.130 |
Why?
|
| Young Adult | 6 | 2020 | 9935 | 0.130 |
Why?
|
| Surgeons | 2 | 2020 | 284 | 0.130 |
Why?
|
| Fatty Liver | 1 | 2018 | 211 | 0.120 |
Why?
|
| Patient Participation | 1 | 2019 | 240 | 0.120 |
Why?
|
| Blotting, Western | 3 | 2013 | 1085 | 0.120 |
Why?
|
| Program Development | 1 | 2017 | 190 | 0.120 |
Why?
|
| Foreign-Body Migration | 1 | 2016 | 60 | 0.120 |
Why?
|
| Length of Stay | 2 | 2011 | 1380 | 0.120 |
Why?
|
| Mentoring | 1 | 2017 | 83 | 0.120 |
Why?
|
| Child Welfare | 1 | 2015 | 64 | 0.120 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2015 | 40 | 0.120 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 163 | 0.120 |
Why?
|
| Ultrasonography, Interventional | 1 | 2017 | 208 | 0.120 |
Why?
|
| Foreskin | 1 | 2015 | 4 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 680 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2016 | 240 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2023 | 901 | 0.120 |
Why?
|
| Europe | 1 | 2016 | 372 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 150 | 0.120 |
Why?
|
| Calcium Signaling | 1 | 2017 | 254 | 0.110 |
Why?
|
| Embryonic Stem Cells | 1 | 2016 | 173 | 0.110 |
Why?
|
| Electrocoagulation | 1 | 2015 | 32 | 0.110 |
Why?
|
| Triage | 1 | 2016 | 148 | 0.110 |
Why?
|
| Skin Transplantation | 1 | 2015 | 54 | 0.110 |
Why?
|
| Ureterocele | 1 | 2014 | 4 | 0.110 |
Why?
|
| Drainage | 1 | 2016 | 265 | 0.110 |
Why?
|
| Muscle, Smooth | 1 | 2015 | 131 | 0.110 |
Why?
|
| Ureteroscopy | 1 | 2014 | 20 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2017 | 461 | 0.110 |
Why?
|
| Penis | 2 | 2020 | 101 | 0.110 |
Why?
|
| United States Food and Drug Administration | 2 | 2025 | 158 | 0.110 |
Why?
|
| Recurrence | 1 | 2018 | 1454 | 0.110 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2016 | 222 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2017 | 2512 | 0.110 |
Why?
|
| Prenatal Diagnosis | 1 | 2018 | 634 | 0.100 |
Why?
|
| Age Factors | 3 | 2019 | 2922 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 1 | 2016 | 617 | 0.100 |
Why?
|
| Training Support | 2 | 2020 | 18 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 723 | 0.100 |
Why?
|
| Pain, Postoperative | 2 | 2019 | 274 | 0.100 |
Why?
|
| Survivors | 1 | 2015 | 358 | 0.100 |
Why?
|
| Orchiopexy | 1 | 2012 | 2 | 0.100 |
Why?
|
| Surgical Flaps | 1 | 2015 | 192 | 0.100 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2013 | 86 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 425 | 0.100 |
Why?
|
| Receptors, Interleukin-3 | 1 | 2012 | 4 | 0.100 |
Why?
|
| Laser Therapy | 1 | 2015 | 232 | 0.100 |
Why?
|
| DNA Primers | 1 | 2013 | 637 | 0.100 |
Why?
|
| Transcriptome | 1 | 2019 | 1123 | 0.090 |
Why?
|
| CpG Islands | 1 | 2013 | 345 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 861 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2016 | 778 | 0.090 |
Why?
|
| Trinucleotide Repeats | 1 | 2011 | 109 | 0.090 |
Why?
|
| Interleukin-8 | 1 | 2012 | 212 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 163 | 0.090 |
Why?
|
| Incisor | 1 | 2010 | 7 | 0.090 |
Why?
|
| Miniaturization | 1 | 2010 | 26 | 0.090 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2010 | 39 | 0.080 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 2444 | 0.080 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 803 | 0.080 |
Why?
|
| Receptors, Notch | 1 | 2012 | 213 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 3 | 2017 | 13 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2016 | 697 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1722 | 0.080 |
Why?
|
| COUP Transcription Factor II | 1 | 2010 | 98 | 0.080 |
Why?
|
| Exercise | 1 | 2015 | 859 | 0.080 |
Why?
|
| Infertility, Male | 1 | 2012 | 296 | 0.080 |
Why?
|
| Parents | 2 | 2019 | 1080 | 0.080 |
Why?
|
| Electroporation | 1 | 2008 | 34 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2013 | 1226 | 0.070 |
Why?
|
| Receptors, Androgen | 1 | 2011 | 410 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 2008 | 93 | 0.070 |
Why?
|
| Mice, Transgenic | 3 | 2024 | 2453 | 0.070 |
Why?
|
| Viral Proteins | 1 | 2010 | 358 | 0.070 |
Why?
|
| Female Urogenital Diseases | 1 | 2008 | 8 | 0.070 |
Why?
|
| Dissection | 1 | 2008 | 59 | 0.070 |
Why?
|
| Renal Veins | 1 | 2008 | 34 | 0.070 |
Why?
|
| Male Urogenital Diseases | 1 | 2008 | 16 | 0.070 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2008 | 37 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 899 | 0.070 |
Why?
|
| Hemangioma, Cavernous | 1 | 2008 | 20 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 757 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2020 | 6530 | 0.070 |
Why?
|
| Urinary Incontinence | 1 | 2008 | 79 | 0.070 |
Why?
|
| Perinatal Mortality | 2 | 2019 | 44 | 0.070 |
Why?
|
| Insulin | 2 | 2020 | 1167 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2010 | 827 | 0.070 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2008 | 97 | 0.070 |
Why?
|
| Stress, Mechanical | 2 | 2019 | 174 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2022 | 377 | 0.070 |
Why?
|
| Transfection | 1 | 2008 | 999 | 0.060 |
Why?
|
| Risk Factors | 6 | 2016 | 10899 | 0.060 |
Why?
|
| Testis | 1 | 2008 | 423 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2020 | 5148 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 3698 | 0.060 |
Why?
|
| Models, Animal | 2 | 2019 | 470 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2019 | 3873 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 278 | 0.060 |
Why?
|
| Research Support as Topic | 1 | 2005 | 63 | 0.060 |
Why?
|
| Device Approval | 1 | 2024 | 12 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3854 | 0.050 |
Why?
|
| Inventions | 1 | 2024 | 20 | 0.050 |
Why?
|
| Thiadiazoles | 1 | 2024 | 6 | 0.050 |
Why?
|
| Meninges | 1 | 2024 | 22 | 0.050 |
Why?
|
| Spinal Dysraphism | 2 | 2019 | 274 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2016 | 316 | 0.050 |
Why?
|
| Pyrazines | 1 | 2024 | 72 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 4764 | 0.050 |
Why?
|
| Cystectomy | 1 | 2004 | 165 | 0.050 |
Why?
|
| Texas | 3 | 2017 | 3632 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2016 | 604 | 0.050 |
Why?
|
| Thrombosis | 1 | 2008 | 530 | 0.050 |
Why?
|
| Foreign Bodies | 1 | 2004 | 110 | 0.050 |
Why?
|
| Urinalysis | 1 | 2023 | 68 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2016 | 757 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 764 | 0.050 |
Why?
|
| Internship and Residency | 2 | 2020 | 1253 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2019 | 880 | 0.050 |
Why?
|
| Biological Products | 1 | 2024 | 137 | 0.050 |
Why?
|
| Etretinate | 1 | 1981 | 1 | 0.050 |
Why?
|
| Vitamin E | 1 | 1981 | 63 | 0.050 |
Why?
|
| Digestive System | 1 | 1981 | 65 | 0.050 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2012 | 54 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 3020 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2012 | 3061 | 0.040 |
Why?
|
| Rabbits | 1 | 2022 | 688 | 0.040 |
Why?
|
| Hydrocephalus | 1 | 2024 | 276 | 0.040 |
Why?
|
| Nurse Anesthetists | 1 | 2020 | 12 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2007 | 550 | 0.040 |
Why?
|
| Sacrococcygeal Region | 1 | 2020 | 36 | 0.040 |
Why?
|
| Anesthesia, Caudal | 1 | 2020 | 15 | 0.040 |
Why?
|
| Anesthesiologists | 1 | 2020 | 39 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 2 | 2012 | 164 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2020 | 141 | 0.040 |
Why?
|
| Research Design | 1 | 2024 | 743 | 0.040 |
Why?
|
| Urinary Calculi | 1 | 1999 | 19 | 0.040 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2020 | 124 | 0.040 |
Why?
|
| Child, Hospitalized | 1 | 2020 | 76 | 0.040 |
Why?
|
| Genitalia, Male | 1 | 2019 | 35 | 0.040 |
Why?
|
| Oligohydramnios | 1 | 2019 | 48 | 0.040 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2019 | 170 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 1038 | 0.040 |
Why?
|
| Dextrans | 1 | 2018 | 48 | 0.040 |
Why?
|
| Genotype | 2 | 2017 | 2706 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 1294 | 0.040 |
Why?
|
| Uterus | 1 | 2022 | 547 | 0.040 |
Why?
|
| Documentation | 1 | 2019 | 121 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 258 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 438 | 0.040 |
Why?
|
| Cadherins | 1 | 2019 | 180 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 1046 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2017 | 100 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 2018 | 109 | 0.030 |
Why?
|
| Electromyography | 1 | 2017 | 140 | 0.030 |
Why?
|
| Injections | 1 | 2017 | 153 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2017 | 10 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2017 | 24 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2019 | 437 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 307 | 0.030 |
Why?
|
| Administration, Intravesical | 1 | 2016 | 33 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2018 | 152 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2017 | 101 | 0.030 |
Why?
|
| Machine Learning | 1 | 2020 | 347 | 0.030 |
Why?
|
| Video Recording | 1 | 2017 | 204 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 482 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 131 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2023 | 888 | 0.030 |
Why?
|
| Morbidity | 1 | 2016 | 251 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2017 | 328 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2020 | 1121 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2016 | 229 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2017 | 443 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2012 | 2679 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2016 | 365 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 311 | 0.030 |
Why?
|
| France | 1 | 2015 | 89 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 364 | 0.030 |
Why?
|
| Brazil | 1 | 2015 | 138 | 0.030 |
Why?
|
| Fatigue | 1 | 2015 | 198 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 433 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2017 | 796 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 500 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 444 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 1228 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 438 | 0.030 |
Why?
|
| Renal Replacement Therapy | 1 | 2015 | 157 | 0.030 |
Why?
|
| Health Facilities | 1 | 2014 | 67 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2017 | 492 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 545 | 0.030 |
Why?
|
| Receptors, Interleukin-8 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Receptors, Interleukin-8A | 1 | 2012 | 8 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1569 | 0.020 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2012 | 15 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 33 | 0.020 |
Why?
|
| Hypertension | 1 | 2001 | 1387 | 0.020 |
Why?
|
| Hernia, Inguinal | 1 | 2012 | 44 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 564 | 0.020 |
Why?
|
| California | 1 | 2012 | 140 | 0.020 |
Why?
|
| Motor Activity | 1 | 2015 | 521 | 0.020 |
Why?
|
| RGS Proteins | 1 | 2012 | 47 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 2012 | 98 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2022 | 2494 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2012 | 27 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1306 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 60 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2015 | 408 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 2184 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 2553 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 215 | 0.020 |
Why?
|
| Amelogenesis | 1 | 2010 | 3 | 0.020 |
Why?
|
| Ameloblasts | 1 | 2010 | 5 | 0.020 |
Why?
|
| Wound Healing | 1 | 2015 | 480 | 0.020 |
Why?
|
| Tooth Abnormalities | 1 | 2010 | 12 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 803 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 2657 | 0.020 |
Why?
|
| Embryonic Development | 1 | 2012 | 221 | 0.020 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2010 | 11 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 571 | 0.020 |
Why?
|
| ELAV Proteins | 1 | 2010 | 14 | 0.020 |
Why?
|
| Maxilla | 1 | 2010 | 39 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2015 | 1078 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2012 | 359 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2010 | 253 | 0.020 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2010 | 37 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2010 | 54 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2010 | 118 | 0.020 |
Why?
|
| Mandible | 1 | 2010 | 82 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 197 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2010 | 68 | 0.020 |
Why?
|
| Middle Aged | 2 | 2001 | 28922 | 0.020 |
Why?
|
| RNA Stability | 1 | 2010 | 83 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 541 | 0.020 |
Why?
|
| Doxycycline | 1 | 2010 | 121 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2010 | 160 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 2303 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 666 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 761 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 982 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 816 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 1051 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 2224 | 0.020 |
Why?
|
| Buffers | 1 | 2008 | 32 | 0.020 |
Why?
|
| Sarcoma, Kaposi | 1 | 2010 | 131 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2010 | 333 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 1997 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 460 | 0.020 |
Why?
|
| Phosphates | 1 | 2008 | 115 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 295 | 0.020 |
Why?
|
| RNA Interference | 1 | 2010 | 516 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 891 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 856 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2012 | 688 | 0.020 |
Why?
|
| Lung | 1 | 2015 | 1556 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 3982 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 381 | 0.020 |
Why?
|
| Korea | 1 | 2007 | 34 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 4541 | 0.020 |
Why?
|
| Regenerative Medicine | 1 | 2007 | 35 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 691 | 0.020 |
Why?
|
| Cell Survival | 1 | 2008 | 869 | 0.020 |
Why?
|
| International Cooperation | 1 | 2007 | 165 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 623 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 1735 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2010 | 605 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 686 | 0.020 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2007 | 165 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2010 | 815 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 2730 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 1441 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 1879 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 825 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1596 | 0.010 |
Why?
|
| Gastric Juice | 1 | 1981 | 15 | 0.010 |
Why?
|
| Biliary Tract | 1 | 1981 | 13 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1554 | 0.010 |
Why?
|
| Pancreas | 1 | 1981 | 222 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 3358 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 1684 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 1483 | 0.010 |
Why?
|
| Rats | 1 | 1981 | 3612 | 0.010 |
Why?
|